If neurohormonal dysfunction plays a role in arrhythmogenesis and SCD in HD patients, aldosterone receptor blockade might modify the CV risk, as the Randomized Aldactone Evaluation Study [33] and Dialysis Outcomes Heart Failure Aldactone Study [34] previously reported, and the CV risk may be controlled by NT-proBNP and QTc-driven management strategies. The gene discussed is NR3C2; the disease is Huntington disease.